← Back to Search

Angiotensin II Receptor Blocker

Candesartan for High Blood Pressure in Obesity (END-RF Trial)

Q: What pathological issues does Candesartan address?

Whilst often used to manage hypesthesia, candesartan has also been effective in combating dialysis therapy, NYHA functional class II-IV <a href="https://www.withpower.com/clinical-trials/heart-failure">heart failure</a> and <a href="https://www.withpower.com/clinical-trials/thyroid-cancer">thyroid cancer</a>.

Q: Who has been deemed eligible to participate in this medical research?

Eligible participants for this medical experiment must be between 18-40 years old and have a diagnosis of <a href="https://www.withpower.com/clinical-trials/hypertension">hypertension</a>. Approximately 25 people will join the trial.

Q: Is enrollment for this experiment still open?

As indicated on the clinicaltrials.gov website, this medical trial does not presently require participants. It was first posted on May 21st 2018 and last updated July 18th 2022; however, there are 1692 other studies actively recruiting right now.

Q: Is this research endeavor open to participants aged 40 or older?

According to the clinical trial's guidelines, individuals aged 18-40 are eligible for enrollment. Patients under 18 and those over 65 can find alternative studies as there is a total of 255 trials targeting minors and 1247 specifically geared towards the elderly demographic.

Q: What is the scope of enrollment for this clinical trial?

Currently, this clinical trial is not enrolling applicants. The original posting date was May 21st 2018 and the last update occurred on July 18th 2022. If you are looking for other studies related to <a href="https://www.withpower.com/clinical-trials/hypertension">hypertension</a> or Candesartan, there happen to be 1673 active trials and 19 recruiting programs respectively.

Phase < 1

Waitlist Available

Led By Ryan Harris, PHD, CES

Research Sponsored by Augusta University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adult between the ages of 18-40 years old

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre-treatment baseline and 7 days post-treatment

Awards & highlights

END-RF Trial Summary

This trial will explore how obesity affects blood pressure levels and if high blood pressure in obesity is due to a dysfunction of the ETB receptor.

Who is the study for?

This trial is for adults aged 18-40 who are dealing with high blood pressure and obesity. It's not open to those with cardiovascular, lung, kidney, liver, brain diseases or metabolic disorders; pregnant individuals; people on meds that affect blood vessels or anticoagulants like aspirin; those with anemia, postmenopausal women, or uncontrolled hypertension.Check my eligibility

What is being tested?

The study is testing the effects of Candesartan (a drug) against a placebo to see if it can improve how well ETB receptors work in obese individuals. This could help understand if these receptors play a role in developing high blood pressure due to obesity.See study design

What are the potential side effects?

Candesartan may cause dizziness, increased potassium levels which can affect heart rhythm, low blood pressure especially after standing up quickly, and possible kidney problems. Placebos typically have no active ingredients but can lead to perceived side effects.

END-RF Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 40 years old.

END-RF Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre-treatment baseline and 7 days post-treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre-treatment baseline and 7 days post-treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-treatment baseline and 7 days post-treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage Change in Flow-Mediated Dilation (FMD)

Side effects data

From 2008 Phase 4 trial • 315 Patients • NCT00348686

Headache

Dizziness

100%

80%

60%

40%

20%

Study treatment Arm

Candesartan

END-RF Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: CandesartanExperimental Treatment1 Intervention

Sub chronic (7 days) Candesartan (16 mg/day)

Group II: PlaceboPlacebo Group1 Intervention

Endothelial function will be determined following a seven day treatment of placebo

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Candesartan

2005

Completed Phase 4

~11970

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH

3,834 Previous Clinical Trials

47,309,471 Total Patients Enrolled

Augusta UniversityLead Sponsor

210 Previous Clinical Trials

85,003 Total Patients Enrolled

Ryan Harris, PHD, CES4.7122 ReviewsPrincipal Investigator - Augusta University

Medical School - University of Kansas, Kansas City, Doctor of Medicine

Augusta University, Medical College of Georgia, Residency in Otolaryngology and Head and Neck Surgery

5Patient Review

The Dr. and his staff were very friendly and efficient. I would highly recommend them to anyone looking for great dental care.

Media Library

Candesartan (Angiotensin II Receptor Blocker) Clinical Trial Eligibility Overview. Trial Name: NCT03583866 — Phase < 1

High Blood Pressure Research Study Groups: Candesartan, Placebo

High Blood Pressure Clinical Trial 2023: Candesartan Highlights & Side Effects. Trial Name: NCT03583866 — Phase < 1

Candesartan (Angiotensin II Receptor Blocker) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03583866 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What pathological issues does Candesartan address?

"Whilst often used to manage hypesthesia, candesartan has also been effective in combating dialysis therapy, NYHA functional class II-IV heart failure and thyroid cancer."

Answered by AI

Who has been deemed eligible to participate in this medical research?

"Eligible participants for this medical experiment must be between 18-40 years old and have a diagnosis of hypertension. Approximately 25 people will join the trial."

Answered by AI

Is enrollment for this experiment still open?

"As indicated on the clinicaltrials.gov website, this medical trial does not presently require participants. It was first posted on May 21st 2018 and last updated July 18th 2022; however, there are 1692 other studies actively recruiting right now."

Answered by AI

Is this research endeavor open to participants aged 40 or older?

"According to the clinical trial's guidelines, individuals aged 18-40 are eligible for enrollment. Patients under 18 and those over 65 can find alternative studies as there is a total of 255 trials targeting minors and 1247 specifically geared towards the elderly demographic."

Answered by AI

What is the scope of enrollment for this clinical trial?

"Currently, this clinical trial is not enrolling applicants. The original posting date was May 21st 2018 and the last update occurred on July 18th 2022. If you are looking for other studies related to hypertension or Candesartan, there happen to be 1673 active trials and 19 recruiting programs respectively."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Adiposity and Endothelin Receptor Function

Ryan Harris 2018. "Adiposity and Endothelin Receptor Function". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03583866.

All > Blood Pressure > High Blood Pressure